β¨ Medicine Distribution Consents
2494 NEW ZEALAND GAZETTE, No. 101 19 AUGUST 2004
Product:
Emend
Active Ingredient:
Aprepitant 80mg
Dosage Form:
Capsule
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
Merck & Co Inc, West Point, Pennsylvania, United States of America
Dated this 10th day of August 2004.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go5393
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product:
Stalevo
Active Ingredients:
Carbidopa monohydrate 27mg equivalent to carbidopa 25mg
Entacapone 200mg
Levodopa 100mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Orion Pharma, Espoo, Finland
Product:
Stalevo
Active Ingredients:
Carbidopa monohydrate 40.5mg equivalent to carbidopa 37.5mg
Entacapone 200mg
Levodopa 150mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Orion Pharma, Espoo, Finland
Product:
Stalevo
Active Ingredients:
Carbidopa monohydrate 13.5mg equivalent to carbidopa 12.5mg
Entacapone 200mg
Levodopa 50mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Orion Pharma, Espoo, Finland
Product:
Topistin
Active Ingredient:
Ciprofloxacin lactate 2.544mg/mL equivalent to Ciprofloxacin 2.00 mg/mL
Dosage Form:
Solution for infusion
New Zealand Sponsor:
AFT Pharmaceuticals Limited
Manufacturer:
Elpen SA, Pikermi Attica, Greece
Dated this 12th day of August 2004.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go5437
Consent to the Distribution of a Changed Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the Schedule hereto:
Schedule
Product:
Diovan
Active Ingredient:
Valsartan 160mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Product:
Diovan
Active Ingredient:
Valsartan 40mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2004, No 101
Gazette.govt.nz —
NZ Gazette 2004, No 101
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of a New Medicine
(continued from previous page)
π₯ Health & Social Welfare10 August 2004
Medicines Act 1981, New Medicine, Emend, Aprepitant, Merck Sharp & Dohme
- DON MATHESON, Deputy Director-General, Public Health
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare12 August 2004
Medicines Act 1981, New Medicines, Stalevo, Carbidopa, Entacapone, Levodopa, Topistin, Ciprofloxacin
- DON MATHESON, Deputy Director-General, Public Health
π₯ Consent to the Distribution of a Changed Medicine
π₯ Health & Social Welfare12 August 2004
Medicines Act 1981, Changed Medicine, Diovan, Valsartan
- DON MATHESON, Deputy Director-General, Public Health